Readers should consult a qualified clinician before considering any compound discussed in this article.
Semaglutide appears to reduce alcohol cravings, according to a recent clinical trial, and this finding could reshape how Canadian users approach both weight management and alcohol use. The study, published in JAMA Psychiatry in early 2025, showed that weekly semaglutide injections cut alcohol consumption and craving in people with alcohol use disorder. For Canadians, this adds a new dimension to semaglutide's benefits beyond its approved uses for type 2 diabetes and weight loss.
The trial enrolled 48 non-treatment-seeking adults with moderate alcohol use disorder. Participants received either semaglutide (escalating to 1.0 mg weekly) or a placebo for nine weeks. The primary outcome was the change in alcohol consumption measured in a lab setting. Those on semaglutide drank significantly less and reported lower cravings. The effect size was notable: a 40% reduction in heavy drinking days compared to placebo. This is the first randomized controlled trial to directly test a GLP-1 receptor agonist for alcohol use, and it builds on a wave of anecdotal reports and animal studies.
For Canadian users, the semaglutide dosage for weight loss in Canada typically starts at 0.25 mg and titrates up to 2.4 mg weekly. The alcohol study used a lower target dose of 1.0 mg, suggesting that even moderate doses may curb drinking. However, Health Canada has not approved semaglutide for alcohol use disorder, and off-label use should be discussed with a doctor. The drug is available in Canada as Ozempic (for diabetes) and Wegovy (for weight loss), though supply shortages have been an issue.
How does semaglutide dampen alcohol cravings? The drug mimics GLP-1, a gut hormone that regulates appetite and blood sugar. GLP-1 receptors are also found in brain areas linked to reward and addiction, such as the nucleus accumbens. By activating these receptors, semaglutide may blunt the dopamine surge that alcohol normally triggers, making drinking less rewarding. This mechanism overlaps with its effect on food cravings, which is why many users report losing interest in both high-calorie foods and alcohol. The Tirzepatide vs Semaglutide for weight loss comparison shows that while both reduce appetite, semaglutide's impact on alcohol may be more pronounced due to its longer half-life and stronger GLP-1 receptor affinity.
The study's implications are significant for the roughly 6 million Canadians who engage in heavy drinking. Alcohol use disorder is undertreated, with existing medications like naltrexone and acamprosate showing modest efficacy. Semaglutide could offer a dual benefit for those who also struggle with obesity or diabetes. In Canada, where obesity rates exceed 25%, many patients may already be on semaglutide for weight loss and could experience reduced drinking as a side benefit. However, experts caution that more research is needed before semaglutide becomes a standard treatment for alcohol problems.
Real-world evidence aligns with the trial data. Online forums and social media are filled with stories of people on semaglutide who suddenly lose the desire to drink. Some describe it as a "switch flipping" where alcohol no longer holds appeal. This phenomenon has sparked interest in using GLP-1 drugs for other addictions, including smoking and opioids. A 2024 analysis of electronic health records found that people prescribed semaglutide or similar drugs had a 50% lower rate of alcohol-related hospitalizations compared to those on other diabetes medications. These findings strengthen the case for semaglutide's role in addiction medicine.
For Canadians considering semaglutide for alcohol cravings, practical considerations matter. The drug is expensive if not covered by insurance, with monthly costs ranging from $200 to $400 CAD. Provincial drug plans may cover Ozempic for diabetes but not for weight loss or off-label uses. Some users turn to compounding pharmacies or online peptide vendors, but this carries risks. If you're looking to buy GLP-1 for weight loss in Quebec, ensure the source is reputable and requires a prescription. Unregulated products may be contaminated or incorrectly dosed.
Side effects are another factor. The most common ones are gastrointestinal: nausea, vomiting, and diarrhea. These usually subside after a few weeks. In the alcohol study, semaglutide was well-tolerated, with no serious adverse events. However, combining semaglutide with heavy drinking could worsen dehydration or pancreatitis risk. Anyone using semaglutide should moderate alcohol intake and stay hydrated. Long-term safety data in people with alcohol use disorder are lacking, so medical supervision is crucial.
The study's lead author, Dr. Christian Hendershot, noted that the effect size was comparable to or larger than existing alcohol medications. Yet the trial was small and short. Larger, longer studies are underway to confirm the findings and explore optimal dosing. One question is whether the craving reduction persists after stopping the drug. Animal studies suggest the effect may wane once GLP-1 signaling returns to normal, so continuous treatment might be necessary.
Canadian researchers are also paying attention. The Canadian Centre on Substance Use and Addiction has flagged GLP-1 agonists as a promising area. A team at the Centre for Addiction and Mental Health in Toronto is planning a pilot study of semaglutide for alcohol use disorder in a Canadian population. This could provide locally relevant data on effectiveness and cost-effectiveness within the Canadian healthcare system.
For now, the new study offers hope but not a green light for self-medication. If you're a Canadian struggling with alcohol cravings and excess weight, talk to your doctor about whether semaglutide might be appropriate. It's not a magic bullet, but it could be a valuable tool. The link between semaglutide and bone density is another area of emerging research, reminding us that these drugs have complex effects beyond weight loss.
In summary, the 2025 JAMA Psychiatry study provides strong preliminary evidence that semaglutide reduces alcohol cravings and consumption. For Canadian users, this adds a compelling reason to consider the drug, especially if they have co-occurring obesity or diabetes. However, off-label use requires careful medical guidance, and access remains a challenge due to cost and supply issues. As research advances, semaglutide may one day be a standard part of addiction treatment in Canada and beyond.